Health CarePharmaceuticals and Biotechnology
  • Price (DKK)340.20
  • Today's Change-4.90 / -1.42%
  • Shares traded145.06k
  • 1 Year change-22.66%
  • Beta0.8156
Data delayed at least 15 minutes, as of May 31 2023 12:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

  • Revenue in DKK (TTM)17.81bn
  • Net income in DKK3.63bn
  • Incorporated2000
  • Employees6.79k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NZYM B:CPH since
Chr Hansen Holding A/SAnnounced12 Dec 202212 Dec 2022Announced-21.07%1.81bn
Chr Hansen Holding A/SAnnounced12 Dec 202212 Dec 2022Announced-21.07%9.62bn
Data delayed at least 15 minutes, as of May 31 2023 12:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Azelis Group NV30.60bn1.59bn41.78bn3.83k25.232.2618.481.370.91170.911717.5710.200.91745.788.371,074,275.004.89--6.06--23.00--5.33--0.83747.520.3705--45.34--214.65------
Turkiye Sise ve Cam Fabrikalari AS36.17bn6.14bn43.74bn24.90k6.941.665.,281,411.0014.2612.9021.8818.9334.1334.3217.8020.921.29--0.336413.02197.4353.15113.9973.6454.0438.75
Arkema SA83.32bn5.60bn46.79bn21.10k8.570.85484.330.56169.779.77147.0997.950.82075.916.59548,059.905.646.966.958.4020.8321.826.878.331.5914.590.328827.3121.346.77-26.6011.949.728.13
Umicore SA189.44bn4.24bn49.18bn11.57k11.321.837.330.25962.372.37105.6814.642.687.5913.892,199,354.006.035.1710.168.586.506.282.251.940.7637.850.396630.445.7416.31-7.9321.545.462.71
Imcd NV34.27bn2.33bn60.40bn4.32k25.884.8419.401.765.505.5080.8329.391.336.256.961,064,421.009.056.6512.439.2622.0720.876.805.341.0413.830.362844.1833.9519.2651.0532.2910.6630.76
Akron PAO15.78bn5.37bn64.04bn11.21k12.087.889.794.061,562.541,562.544,595.302,395.290.73542.9921.09--25.348.4035.9812.1759.9047.3434.4615.831.10--0.448981.994.385.43-86.33-26.953.50-19.73
Evonik Industries AG134.02bn2.03bn66.97bn33.92k32.690.83794.730.49970.59020.592438.5623.030.79814.748.20528,813.701.263.111.603.7321.5126.781.584.590.9947--0.29283.6423.625.15-27.94-5.44-3.620.3454
Yara International ASA153.38bn13.44bn67.39bn17.50k5.021.113.340.439485.0385.03970.71383.641.223.808.7914,131,960.0010.685.4514.697.1125.5827.098.775.891.0811.030.325268.8743.8416.05518.4942.24-7.2552.98
Chr Hansen Holding A/S9.63bn1.70bn68.40bn3.69k40.135.1327.077.1012.9312.9373.18101.200.39953.236.922,607,823.007.068.947.9911.0954.7457.5717.6721.000.970210.090.367762.4613.052.7713.290.0985.96-10.07
Novozymes A/S17.81bn3.63bn78.43bn6.79k26.487.4215.294.4013.0313.0363.9646.500.66492.354.912,765,611.0013.6214.7718.8519.5354.2256.2620.4921.310.806623.910.383947.3717.403.8516.853.3411.305.92
Brenntag SE144.66bn6.36bn86.16bn17.50k13.552.629.340.59565.525.52125.7828.541.768.707.081,107,372.007.856.3012.148.8822.2822.404.463.901.0817.910.412935.9535.0910.5997.8119.7012.0312.70
PhosAgro PAO-9.23bn-9.23bn90.77bn25.00k--5.95----------1,277.21----------24.15--30.90--46.59--23.350.7324--0.564787.7935.4425.7242.3848.7812.2080.76
Akzo Nobel NV81.76bn2.26bn90.88bn32.90k41.022.7617.531.111.751.6863.2525.900.72423.824.21311,875.002.163.953.485.6035.7441.072.996.180.77299.090.555167.8313.132.45-56.01-3.783.15-6.78
Data as of May 31 2023. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK

Institutional shareholders

17.99%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 25 May 20236.84m3.01%
The Vanguard Group, Inc.as of 05 May 20235.33m2.35%
Norges Bank Investment Managementas of 31 Dec 20224.83m2.12%
MFS International (UK) Ltd.as of 30 Apr 20234.79m2.11%
BlackRock Fund Advisorsas of 04 May 20233.79m1.67%
Impax Asset Management Ltd.as of 28 Apr 20233.78m1.66%
Pictet Asset Management SAas of 30 Apr 20233.57m1.57%
Handelsbanken Fonder ABas of 30 Apr 20233.02m1.33%
Harding Loevner LPas of 30 Apr 20232.60m1.14%
Walter Scott & Partners Ltd.as of 25 May 20232.33m1.03%
More ▼
Data from 31 Dec 2022 - 30 Apr 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.